S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
UK's Truss sticks by economic plan as her party worries

Abbott Labs Stock Can Be a Recession Hedge for Your Portfolio

Abbott Labs Stock Can Be a Recession Hedge for Your Portfolio

Diversified global medical science products maker Abbott (NYSE: ABT) stock is down a modest (-11.5%) on the year. Abbott provides full lifecycle health and medical products from baby formula to nutrition supplement products, chronic disease treatments and medical devices to generic pharmaceuticals. Healthcare is one of the few recession proof sectors and Abbott’s portfolio of life cycle products enables it to remain stable even during economic downturns. The Company generates over $3 billion annually in COVID-related products. It also controls nearly 43% of the U.S. baby formula market. The baby formula shortage has accelerated the resumption of Abbott’s baby formula plant in Sturgis, Michigan in July 2022 after being shut down for months due to safety concerns. The Biden administration invoked the Defense Production Act to increase baby formula production prompting Abbott to collaborate with the FDA in reopening the plant. It’s FreeStyle Libre device, which provides blood glucose reading without the need for a fingerstick, saw 25% growth in sales as it grew its user base to four million. It’s pacemaker business competes with the likes of Medtronic (NYSE: MDT). The Company is a resilient stalwart during times of economic stress. The Company has provided shareholders with a consistent dividend since 1924 . Prudent investors seeking a potential defensive recession hedge in a proven medical science and healthcare Company can watch for opportunistic pullbacks in shares of Abbott Labs.


Q1 Fiscal 2022 Earnings Release

On Jan. 26, 2022, Abbott released its fiscal fourth-quarter 2022 results for the quarter ending March 2022. The Company reported an earnings-per-share (EPS) profit of $1.73 excluding non-recurring items versus consensus analyst estimates for a profit of $1.46, beating estimates by $0.27. Revenues rose 13.8% year-over-year (YoY) to $11.89 billion beating analyst estimates for $11 billion. Global COVID-19-related sales were $3.3 billion. Abbott CEO Robert Ford commented, "Our diversified business continues to perform well in a challenging environment. We're particularly pleased with the strong performance we're achieving in Medical Devices and Established Pharmaceuticals."

Reaffirms Guidance

Abbott reaffirmed its guidance for fiscal full-year 2022 EPS of at least $4.70 versus $4.84 consensus analyst estimates.  

Conference Call Takeaways

CEO Ford noted that its Established Pharmaceuticals (EPD) sales grew 13.5% hitting its third quarter of double-digit organic growth. Double-digit growth was experienced across multiple countries, and therapeutic areas including respiratory, gastroenterology, and CNS pain management. The Adjust Nutrition business saw 11.5% organic sales growth led by its Ensure and Glucerna brands. The FDA and CDC found no genetic match between strains of salmonella in its factories and products. The Company is prioritizing the mitigation of supply constraints by shipping product from its FDA registered European facility and ramping up production. Diagnostic sales grew 35% of which its COVID test BinaxNOW made up 90% of the $3.5 billion in test sales. Medical Devices rose 11.5% and its Freestyle Libre which eliminates the use of a fingerstick rose 25%. The Company received FDA approval for its leadless pacemaker Aveir to treat patients with slow heart rhythms. FreeStyle Libre received reimbursement in Japan to cover all people who receive insulin daily. The FDA also approved its EnSite X system, which can gives a 360-degree view of the heart. He concluded, So in summary, we're achieving strong growth overall and across several areas of our business. As the first quarter progressed and COVID levels decreased, we saw a steady improvement in the hospital-based procedure trends, which has continued into April. And we continue to advance our pipeline with new products, indications and reimbursement coverage in several attractive growth areas.”

Abbott Labs Stock Can Be a Recession Hedge for Your Portfolio

ABT Opportunistic Pullback Levels

Using the rifle charts on the weekly and daily time frames provides a precision view of the landscape for ABT stock. The weekly rifle chart made a near-term bottom at the $101.21 Fibonacci (fib) level and staged a rally towards the $110.88 weekly market structure low (MSL) buy trigger. The weekly rifle chart resume its downtrend as shares collapsed by under the weekly 5-period moving average (MA) resistance at $107.09 followed  by the weekly 15-period MA at $112.52. The weekly 200-period MA sits at $99.97. The weekly lower Bollinger Bands (BBs) sit at $99.30. The weekly stochastic rejected the 40-band bounce attempt and reversed into a mini inverse pup falling towards the 20-band. The daily rifle chart breakdown triggered as the daily 5-period MA at $107.34 crossed down through the 15-period MA at $108.26 as stochastic formed a mini inverse pup move down through the 60-band. The daily lower BBs sit at $100.74. Prudent investors can watch for opportunistic pullbacks at the $101.21 fib, $97.84 fib, $93.84 fib, $91.47 fib, $88.76 fib, $86.16, and the $82.35 fib level. Upside trajectories range from the $112.52 fib up towards the $129.33 fib level.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Medtronic (MDT)
3.3652 of 5 stars
$80.75-1.8%3.37%20.87Hold$111.52
Abbott Laboratories (ABT)
3.1475 of 5 stars
$96.76-1.6%1.94%20.20Moderate Buy$132.46
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Abbott Laboratories right now?

Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Jea Yu

About Jea Yu

Contributing Author: Trading Strategies

With over 20 years of active participation and analysis of the US equities, options and futures markets, Mr. Yu brings fresh insights into the workings of the financial markets. He has published four books by esteemed publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. His brainchild, the Underground Trader, was voted Forbes Best of the Web for four consecutive years under the active trader category. He has been a featured speaker all over the country at various expos and seminars who enjoys a standing-room-only reception in the largest convention halls from New York to Las Vegas. He has been quoted and featured in USA Today, Wall Street Journal, Traders Magazine and the Financial Times and various trade publications like Stocks & Commodities, Active Trader and Online Investor. Mr. Yu has a B.A. in Liberal Arts and minor in Business Administration from the University of Maryland.
Contact Jea Yu via email at JeaYu21@gmail.com.
Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastFed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC

Axel Merk, President and CIO of Merk Investments has three very different stocks he frames within the current market and economic conditions.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.